Brown & Brown (BRO) has been a hot topic in the bio-tech market. After a 2024 share price pullback, opinions on its valuation greatly vary. Analysts note the market might be overlooking the companies true value, as the stock has significant
price over earnings. Reports indicate shares purchased by
Boston Partners as well as by Rhumbline Advisers despite the company reporting a net profit margin decline that could challenge the growth narrative.
Goldman Sachs has cut BRO's price target, and maintains a neutral rating while Barclays maintains its equal-weight recommendation. Despite recent Soft Results in 2025, there have been narrative shifts with revenue surges and a 10%
dividend hike. Leveraging a period of low performance, the company has authorized a $1.5B buyback, lifting its quarterly dividend by 10%. After a recent 17% share price decline, and with 69% institutional ownership, predictions show optimistic trends for a potential recovery. The company has also expanded its retail division leadership, and analysts anticipate a significant strategic acquisition after
BRO set a $4 billion stock offering. Overall, factors suggest potential growth opportunities for Brown & Brown, but the path ahead is still unclear.
Brown Brown BRO News Analytics from Tue, 25 Feb 2025 08:00:00 GMT to Sat, 29 Nov 2025 08:47:07 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -2
